Communiqués Moderna, Inc.

Actions

MRNA

US60770K1079

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 21:36:26 11/06/2026			Varia. 5j.	Varia. 1 janv.
49,82 ^USD	+8,32%		-3,76%	+68,36%

09/06	Transcript : Moderna, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 03:20 PM
09/06	Ebola Bundibugyo : le point sur les vaccins et traitements en cours de développement	RE

Communiqués

09/06	Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome	AQ
02/06	Moderna to Present at Upcoming Conference in June 2026	AQ
01/06	Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus	AQ
12/05	Moderna Recognized by TIME as One of the World's Most Impactful Companies	AQ
06/05	Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010	AQ
04/05	Moderna : Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
01/05	Moderna : Transcript (MRNA USQ Transcript 2026 05 01 1)	PU
01/05	Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
01/05	Moderna: Q1 Earnings Snapshot	AQ
01/05	Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
22/04	Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines)	PU
22/04	Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate	AQ
21/04	Moderna : ESCMID 2026 (mRNA-1010 Phase 3 sequential administration in adults 50+)	PU
21/04	Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting	AQ
21/04	Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19	AQ
21/04	Moderna to Present at Upcoming Conferences in May 2026	AQ
19/04	Moderna : ESCMID 2026 (mRNA-1345 Phase 3 RSV revaccination 60+ study)	PU
19/04	Moderna : ESCMID 2026 (mRNA-1083 Phase 3 study in adults 50+ in Japan)	PU
17/04	Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting	AQ
15/04	Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026	AQ
07/04	Moderna : to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026	PU
27/02	Moderna : Transcript (MRNA USQ Transcript 2026 01 13 3)	PU
18/02	Moderna says the FDA will consider its new flu shot after resolving a public dispute	AQ
14/02	Moderna : Earnings Transcript (MRNA USQ Transcript 2026 02 13)	PU
13/02	Moderna : Earnings Presentation (ModernaQ25inal)	PU